Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + nintedanib
- Development stage
- Phase 3
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel + nintedanib is a combination therapy used for the treatment of advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology after failure of first-line chemotherapy. Docetaxel is a cytostatic drug, while nintedanib is a triple angiokinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) pathways. This combination blocks proteins that regulate the growth and division of cancer cells, effectively slowing down cancer progression.
- Brand names
- Vargatef
- Other names
- nintedanib esilate + docetaxel
02
Targets
FGFR2 (Keratinocyte growth factor receptor)LCK (Proto-oncogene tyrosine-protein kinase Lck)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + nintedanib.